Etanercept BS MA
Etanercept biosimilar developed by Mochida Pharmaceutical (LG Chem product), development code LBEC0101. Reference product Enbrel.
About Etanercept BS MA
Etanercept BS MA is Mochida's etanercept, the first etanercept biosimilar approved in Japan, in January 2018. The product was developed by LG Chem of Korea, and Mochida sells it in Japan in vials, syringes and pens.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Etanercept BS MA
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Etanercept BS MA holds an approval, these are the other etanercept biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| PMDA | 1 | Lupin (Nepexto / Fubelv / Lupin etanercept) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Mochida Pharmaceutical: Adalimumab BS MA, Pegfilgrastim BS Mochida / Nipro, Teriparatide BS Mochida, Tocilizumab BS MA.
Chronology
- PMDAJan 2018Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning etanercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant